Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRME Prime Medicine, Inc.

Trading 03-26 14:03:54 EDT

3.69

+0.06

+1.52%

High3.84	Low3.56	Vol1.00M
Open3.56	D1 Closing3.63	Amplitude7.58%
Mkt Cap665.18M	Tradable Cap367.76M	Total Shares180.51M
T/O3.74M	T/O Rate1.00%	Tradable Shares99.80M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRME","market":"US","secType":"STK","nameCN":"Prime Medicine, Inc.","latestPrice":3.685,"timestamp":1774548215382,"preClose":3.63,"halted":0,"volume":1001474,"delay":0,"changeRate":0.015151515151515195,"floatShares":99798700,"shares":180510658,"eps":-1.352137,"marketStatus":"Trading","change":0.055,"latestTime":"03-26 14:03:54 EDT","open":3.56,"high":3.835,"low":3.56,"amount":3735312.2465729997,"amplitude":0.075758,"askPrice":3.69,"askSize":2230,"bidPrice":3.68,"bidSize":1520,"shortable":3,"etf":0,"ttmEps":-1.352137,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1774555200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1666238400000,"exchange":"NASDAQ","adjPreClose":3.63,"preHourTrading":{"tag":"盘前","latestPrice":3.52,"preClose":3.63,"latestTime":"09:00 EDT","volume":6901,"amount":24552.1197026,"timestamp":1774530029736,"change":-0.11,"changeRate":-0.030303,"amplitude":0.022039},"postHourTrading":{"tag":"盘后","latestPrice":3.66,"preClose":3.63,"latestTime":"19:51 EDT","volume":5468,"amount":19881.9655,"timestamp":1774482702149,"change":0.03,"changeRate":0.008264,"amplitude":0.008264},"volumeRatio":0.481981,"impliedVol":1.0512,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/PRME","defaultTab":"news","newsList":[{"id":"2616328694","title":"Prime Medicine Publishes Corporate Presentation on Prime Editing Platform and Gene-Editing Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2616328694","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616328694?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:10","pubTimestamp":1772543418,"startTime":"0","endTime":"0","summary":"Prime Medicine Inc. outlined updates on its prime editing gene-editing platform, highlighting its approach to making permanent genetic corrections without double-strand breaks or bystander edits. The company said it is prioritizing liver programs in Wilson disease  and Alpha-1 Antitrypsin Deficiency , with plans to file regulatory submissions in 2026 and begin Phase 1 clinical trials, and to report initial clinical data in 2027. Prime Medicine also described progress in its ex vivo program for chronic granulomatous disease , including plans to move toward a biologics license application following regulatory alignment, and noted ongoing work in cystic fibrosis supported by agreements with the Cystic Fibrosis Foundation, as well as an ex vivo T-cell collaboration with Bristol Myers Squibb. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accur","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL7BbqGb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LU0321505868.SGD","BMY","IE00BJJMRZ35.SGD","LU0225771236.USD","LU0868494617.USD","LU2242652126.USD","BK4534","IE00BFTCPJ56.SGD","LU0096364046.USD","LU0882574055.USD","BK4139","BK4559","BK4581","LU0237698245.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU1868836591.USD","IE0002141913.USD","LU2360032135.SGD","LU1291159041.SGD","LU0321505439.SGD","LU1883839398.USD","LU1093756168.USD","LU1718418525.SGD","LU1868836757.USD","LU2133065610.SGD","LU0267386448.USD","LU2242646821.SGD","LU1261432733.SGD","LU1323610961.USD","LU1868837300.USD","BK4588","IE00BFXG1179.USD","LU1585245621.USD","LU0225284248.USD","IE00BSNM7G36.USD","LU1074936037.SGD","LU1989771016.USD","LU2125154935.USD","PRME","LU1032466523.USD","LU0061475181.USD","LU1670710588.SGD","IE00B2B36J28.USD","LU0306807586.USD","LU0114720955.EUR","LU1670711123.USD","LU0456855351.SGD","LU0985481810.HKD"],"gpt_icon":0},{"id":"2616328614","title":"Earnings Flash (PRME) Prime Medicine Posts 2025 Net Loss $1.35 a Share, vs. FactSet Est of $1.30 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2616328614","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616328614?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:04","pubTimestamp":1772543095,"startTime":"0","endTime":"0","summary":"Earnings Flash (PRME) Prime Medicine Posts 2025 Net Loss $1.35 a Share, vs. FactSet Est of $1.30 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRME"],"gpt_icon":0},{"id":"2616340061","title":"Prime Medicine posts FY 2025 collaboration revenue of USD 4.6 million, up 2.9x","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340061","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340061?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:02","pubTimestamp":1772542928,"startTime":"0","endTime":"0","summary":"Prime Medicine posts FY 2025 collaboration revenue of USD 4.6 million, up 2.9x               Prime Medicine said its FY 2025 net loss attributable to common stockholders was USD 201.1 million, with a ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nNDL40qSFf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868836591.USD","LU1883839398.USD","IE00B3QW5Z07.USD","LU2125154935.USD","PRME","LU1670710588.SGD","IE00BJJMRZ35.SGD","BK4112","LU0061475181.USD","LU0225771236.USD","LU1868836914.USD","LU0321505868.SGD","LU2095319765.USD","LU0306806265.USD","LU2133065610.SGD","LU2360032135.SGD","BK4534","BK4559","LU1670710661.SGD","LU1868836757.USD","LU1093756325.SGD","LU0868494617.USD","SG9999014005.SGD","IE0009355771.USD","LU0267386448.USD","IE00BFTCPJ56.SGD","LU2242652126.USD","IE00BGHQF748.EUR","IE0002141913.USD","BK4139","BMY","LU0314104364.USD","IE00BSNM7G36.USD","SG9999014013.SGD","LU1718418525.SGD","NDAQ","IE00BFXG1179.USD","LU1868837136.USD","LU0306807586.USD","IE00B64PRP62.GBP","LU0096364046.USD","BK4532","LU0321505439.SGD","LU1430594728.SGD","LU1585245621.USD","SG9999014021.USD","LU1989771016.USD","LU2125154778.USD","LU1868837300.USD","LU1670711040.USD"],"gpt_icon":0},{"id":"2616340251","title":"BRIEF-Prime Medicine, Inc. FY EPS USD -1.35","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340251","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340251?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542847,"startTime":"0","endTime":"0","summary":"BRIEF-Prime Medicine, Inc. FY EPS USD -1.35\n\n\nMar 03 (Reuters) - Prime Medicine, Inc. FY operating expenses USD 212.982 million.\n\nFY income from operations USD -208.35 million\nFY net income USD -201.142 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLXDB84F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2616404963","title":"Prime Medicine, Inc. FY Income From Operations USD -208.35 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616404963","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616404963?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542802,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLXDB84F6:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2616404833","title":"Prime Medicine, Inc. FY Net Income USD -201.142 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616404833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616404833?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLXDB84F6:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2616340431","title":"Prime Medicine, Inc. FY Operating Expenses USD 212.982 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2616340431","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616340431?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542802,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260303:nPLXDB84F6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2616349328","title":"Press Release: Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2616349328","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616349328?lang=en_us&edition=fundamental","pubTime":"2026-03-03 21:00","pubTimestamp":1772542800,"startTime":"0","endTime":"0","summary":"-- On track to file IND and/or CTA for Wilson Disease and AATD programs in 1H 2026 and mid-2026, respectively; initial clinical data for both expected in 2027 --. -- Ongoing engagement with FDA for PM359 in CGD; plan to submit BLA following final alignment --. -- Prime Medicine reported cash, cash equivalents, investments, and restricted cash of $191M providing cash runway into 2027 --. CAMBRIDGE, Mass., March 03, 2026  -- Prime Medicine, Inc. , a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results for the full year ended December 31, 2025 and provided a business update.Prime Medicine is advancing in vivo gene editing programs aimed at treating two of the most significant genetic liver disorders: Wilson Disease  and Alpha--1 Antitrypsin Deficiency . Prime Medicine anticipates submitting an investigational new drug  and/or clinical trial application  for its anchor WD program  in the first half","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4093","BK4195","BK4139","PRME","LU2463526074.USD","CTA","BK4109","BK4585","WD","BK4588","CF","BK4229","IND","ASH"],"gpt_icon":0},{"id":"2605702924","title":"JonesTrading Sticks to Its Buy Rating for Prime Medicine, Inc. (PRME)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605702924","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605702924?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:56","pubTimestamp":1769172991,"startTime":"0","endTime":"0","summary":"JonesTrading analyst Soumit Roy maintained a Buy rating on Prime Medicine, Inc. today and set a price target of $5.00. According to TipRanks, Roy i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-prime-medicine-inc-prme-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/jonestrading-sticks-to-its-buy-rating-for-prime-medicine-inc-prme-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"gpt_icon":0},{"id":"2593411405","title":"Prime Medicine Initiated at Outperform by LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2593411405","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593411405?lang=en_us&edition=fundamental","pubTime":"2025-12-24 00:22","pubTimestamp":1766506920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 23, 2025 11:22 ET (16:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2593413520","title":"LifeSci Initiates Prime Medicine at Outperform With $6 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2593413520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593413520?lang=en_us&edition=fundamental","pubTime":"2025-12-23 21:53","pubTimestamp":1766497988,"startTime":"0","endTime":"0","summary":"Prime Medicine (PRME) has an average rating of overweight and mean price target of $6.46, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2589872040","title":"Prime Medicine Reports Positive Phase 1/2 Results for PM359 in Chronic Granulomatous Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2589872040","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589872040?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:05","pubTimestamp":1765112709,"startTime":"0","endTime":"0","summary":"Prime Medicine Inc. announced the publication of Phase 1/2 clinical data for PM359, its investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease , in the New England Journal of Medicine. The initial results from two patients in the trial showed rapid neutrophil and platelet engraftment, durable restoration of NADPH oxidase activity, and early clinical benefit without any safety concerns related to PM359. Both patients remained free of new CGD-related complications following treatment. The data will also be presented at the 67th American Society of Hematology  Annual Meeting, scheduled for December 6-9, 2025, in Orlando, Florida.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prime Medicine In","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL6jbdYV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","LU2210149790.SGD","BK4112","LU2210150020.SGD","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","BK4588","SG9999014013.SGD","IE00B3QW5Z07.USD","NDAQ","SG9999014021.USD","PRME","BK4139","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2589720658","title":"Prime Medicine Announces the New England Journal of Medicine Publication of Pm359  Clinical Data for the Treatment of Chronic Granulomatous Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2589720658","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589720658?lang=en_us&edition=fundamental","pubTime":"2025-12-07 21:05","pubTimestamp":1765112700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nTUA2SCVQQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PRME"],"gpt_icon":0},{"id":"1101922585","title":"Stock Track | Prime Medicine (PRME) Plummets 5% Following Analyst's Cautious Hold Rating and Extended Development Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=1101922585","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101922585?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:30","pubTimestamp":1763047823,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc. (PRME) saw its stock price plummet by 5.04% during Thursday's intraday trading session, as investors reacted to a recent analyst report and concerns about the company's...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRME"],"gpt_icon":0},{"id":"1142813530","title":"Stock Track | Prime Medicine (PRME) Plunges 5% Following Analyst's Cautious Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1142813530","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1142813530?lang=en_us&edition=fundamental","pubTime":"2025-11-13 23:30","pubTimestamp":1763047817,"startTime":"0","endTime":"0","summary":"Shares of Prime Medicine, Inc. (PRME) tumbled 5.04% in Thursday's intraday trading session, following a cautious Hold rating from H.C. Wainwright analyst Arthur He CFA. The biotech company, known for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRME"],"gpt_icon":0},{"id":"2583612125","title":"Cautious Hold Rating for Prime Medicine, Inc. Amid Promising Preclinical Results and Extended Development Timeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2583612125","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583612125?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:37","pubTimestamp":1763033836,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Arthur He CFA has reiterated their neutral stance on PRME stock, giving a Hold rating on November 11. Arthur He CFA has giv...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-for-prime-medicine-inc-amid-promising-preclinical-results-and-extended-development-timeline-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cautious-hold-rating-for-prime-medicine-inc-amid-promising-preclinical-results-and-extended-development-timeline-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME"],"gpt_icon":0},{"id":"2582922023","title":"Prime Medicine Is Maintained at Neutral by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2582922023","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582922023?lang=en_us&edition=fundamental","pubTime":"2025-11-12 04:43","pubTimestamp":1762893780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 15:43 ET (20:43 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"1100621035","title":"Stock Track | Prime Medicine Soars 5.25% as CEO Prepares to Speak at Jefferies Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=1100621035","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100621035?lang=en_us&edition=fundamental","pubTime":"2025-11-11 23:02","pubTimestamp":1762873346,"startTime":"0","endTime":"0","summary":"Prime Medicine, Inc. (PRME) saw its stock soar by 5.25% in Tuesday's pre-market trading, catching investors' attention ahead of a significant company event. The biotech firm's shares rallied as...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["PRME"],"gpt_icon":0},{"id":"2582512876","title":"Prime Medicine Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582512876","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582512876?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:31","pubTimestamp":1762777860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRME/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 10, 2025 07:31 ET (12:31 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRME","BK4139"],"gpt_icon":0},{"id":"2581883191","title":"Prime Medicine files automatic mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2581883191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581883191?lang=en_us&edition=fundamental","pubTime":"2025-11-07 21:11","pubTimestamp":1762521062,"startTime":"0","endTime":"0","summary":"08:06 EST Prime Medicine (PRME) files automatic mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-moving...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prime-medicine-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prime-medicine-files-automatic-mixed-securities-shelf-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRME","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.primemedicine.com;investors.primemedicine.com","stockEarnings":[{"period":"1week","weight":0.0283},{"period":"1month","weight":0.0868},{"period":"3month","weight":0.0168},{"period":"6month","weight":-0.291},{"period":"1year","weight":0.8615},{"period":"ytd","weight":0.0461}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0375},{"period":"3month","weight":-0.0486},{"period":"6month","weight":-0.0076},{"period":"1year","weight":0.1414},{"period":"ytd","weight":-0.0368}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is based in Cambridge, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070058},{"month":2,"riseRate":0.5,"avgChangeRate":0.101559},{"month":3,"riseRate":0,"avgChangeRate":-0.216212},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.102761},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.001492},{"month":6,"riseRate":0.666667,"avgChangeRate":0.318071},{"month":7,"riseRate":1,"avgChangeRate":0.211426},{"month":8,"riseRate":0,"avgChangeRate":-0.164067},{"month":9,"riseRate":0.333333,"avgChangeRate":0.111542},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.141809},{"month":11,"riseRate":0.25,"avgChangeRate":-0.086687},{"month":12,"riseRate":0.5,"avgChangeRate":0.02429}],"exchange":"NASDAQ","name":"Prime Medicine, Inc.","nameEN":"Prime Medicine, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Prime Medicine, Inc.,PRME,Prime Medicine, Inc.股票,Prime Medicine, Inc.股票老虎,Prime Medicine, Inc.股票老虎国际,Prime Medicine, Inc.行情,Prime Medicine, Inc.股票行情,Prime Medicine, Inc.股价,Prime Medicine, Inc.股市,Prime Medicine, Inc.股票价格,Prime Medicine, Inc.股票交易,Prime Medicine, Inc.股票购买,Prime Medicine, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Prime Medicine, Inc.(PRME),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Prime Medicine, Inc.(PRME) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction